Q/C Technologies owner swaps warrants for 4.98M shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Q/C Technologies, Inc. (QCLS) reported that 10% owner PharmaCyte Biotech, Inc. exchanged 851,304 Series G warrants for 4,982,272 common shares on November 18, 2026. The post-transaction positions listed were 5,152,000 common shares and 13,318,344 Series G warrants. The 5,152,000 common shares include 169,728 shares acquired as payment of Series G dividends. The exchange share amount was based on the warrants’ Black Scholes value divided by $0.3101, the common stock’s closing price on the last trading day before the agreement. No Rule 10b5-1 plan is reported.
The Form 4 also records the acquisition of 3,000 Series H preferred shares, with 3,000 listed after the transaction. The related note says PharmaCyte consented to extending their maturity from March 2, 2027 to September 2, 2027 for no additional consideration.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| In-the-Money Exercise | Series G Long-Term Warrants F3, F1 | 851,304 | $0.00 | $0.00 |
| Other | Series H Convertible Preferred Stock F4, F5 | 3,000 | $0.00 | $0.00 |
| In-the-Money Exercise | Common stock F1, F2 | 4,982,272 | $0.00 | $0.00 |
Footnotes (5)
- F1. On November 18, 2026, pursuant to a Consent and Warrant Exchange Agreement dated November 15, 2026 (the "Consent Agreement"), between PharmaCyte Biotech, Inc. (the "Reporting Person") and Q/C Technologies, Inc. (the "Issuer"), the Reporting Person exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares of common stock, par value $0.001 per share of the Issuer ("Common Stock"). The number of shares of Common Stock issued was determined based on the Black Scholes value of the exchanged warrants divided by $0.3101 per share, the closing price of the Common Stock on the last trading day prior to execution of the Consent Agreement.
- F2. Includes 169,728 shares of Common Stock acquired as payment of Series G Dividends exempt from Section 16 of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16a-9(a) promulgated thereunder.
- F3. Series G Long-Term Warrants are exercisable for shares of Common Stock at an exercise price of $0.3101 per share, subject to adjustment.
- F4. Each share of Series H Convertible Preferred Stock, with a stated value of $1,000, is convertible at the holder's election into approximately 3,225 shares of Common Stock, based on the current conversion price of $0.3101 per share, subject to adjustment.
- F5. On November 18, 2026, pursuant to the Consent Agreement, the Reporting Person consented to an amendment to the Certificate of Designations extending the maturity date of the Series H Preferred Shares from March 2, 2027 to September 2, 2027, for no additional consideration. Any deemed cancellation pursuant to the amendment is exempted by Rule 16b-6(d), and the cancellation also is exempt from reporting under Rule 16a-4(d)
Key Figures
Key Terms
Series G Long-Term Warrants technical
Black Scholes value financial
Series H Convertible Preferred Stock financial
Certificate of Designations regulatory
Rule 16b-6(d) regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does QCLS’s Series H preferred stock mature after the amendment?
AI-generated analysis. How Rhea-AI works. Not financial advice.